Metabolomics-Driven Biomarker Discovery of Alzheimer’s Disease

Biomarker discovery in Alzheimer’s disease (AD), has been largely focused on proteomics. We hypothesize the existence of AD-specific markers further upstream of the most commonly used marker, amyloid β.

Our project proposal will cover a series of important gaps in previous metabolomic studies of AD, including a bespoke, cutting-edge technology developed by a co-applicant.

We will also apply advanced modelling techniques and even link the findings back to animal models of poor brain clearance and AD. We will also conduct a glycome analysis with a patented technique developed by a co-applicant.

Finally, we will examine the previously unknown hits in cell culture models of AD.Our team is highly multi-disciplinary, consisting of a pre-clinical researcher specializing in animal models, a neurologist with knowledge of AD and access to patient samples and cognitive data, a metabolomics expert with in-depth chemistry expertise, a metabolic modelling expert, a company with a patented technique, and an expert in in vitro studies of AD.

We believe that by integrating all these skills, we will uncover previously unknown metabolic and glycomic clues for AD development than any previous study published hitherto.

This has the potential to identify new drug targets and to develop new diagnostics for the timely diagnosis of AD at the onset. This would reduce the burden of patients and the costs of healthcare systems worldwide.